ID   OVCAR-7
AC   CVCL_DG79
SY   OVCAR7
DR   cancercelllines; CVCL_DG79
DR   GEO; GSM185141
DR   GEO; GSM185142
DR   Progenetix; CVCL_DG79
DR   Wikidata; Q54937013
RX   PubMed=1348364;
RX   PubMed=2307530;
RX   PubMed=9041185;
DI   NCIt; C4908; Ovarian carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 6
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070; PMCID=PMC48805;
RA   Godwin A.K., Meister A., O'Dwyer P.J., Huang C.-S., Hamilton T.C.,
RA   Anderson M.E.;
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=2307530; DOI=10.1002/ijc.2910450306;
RA   Schilder R.J., Hall L., Monks A., Handel L.M., Fornace A.J. Jr.,
RA   Ozols R.F., Fojo A., Hamilton T.C.;
RT   "Metallothionein gene expression and resistance to cisplatin in human
RT   ovarian cancer.";
RL   Int. J. Cancer 45:416-422(1990).
//
RX   PubMed=9041185;
RA   Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.;
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//